Advances in Frontline Gastric, GEJ, and Esophageal Adenocarcinoma From ESMO 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, provide a comprehensive overview of the evolving treatment landscape for advanced gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma, highlighting current standards, unmet needs, and key clinical considerations. They review pivotal data from the EDGE-Gastric trial, discuss the design and potential impact of the phase 3 STAR-221 study, and explore where domvanalimab plus zimberelimab with chemotherapy could ultimately fit within the frontline paradigm. They also spotlight additional practice-informing findings from the 2025 ESMO Congress and outline ongoing research that may further refine therapeutic strategies in gastrointestinal oncology.

EP. 1: Current Standards and Unmet needs in Advanced Gastric/GEJ Cancer

November 17th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss current treatment standards in advanced gastric/GEJ cancer.

EP. 2: EDGE-Gastric Trial: Breaking Down Data for Domvanalimab/Zimberelimab Plus Chemo in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

November 17th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the implications of findings from the phase 2 EDGE-Gastric trial.

EP. 3: Detailing the Ongoing Phase 3 STAR-221 Trial of Domvanalimab/Zimberelimab Plus FOLFOX in First-Line Gastric/GEJ/Esophageal Adenocarcinoma

November 24th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, detail the design of the phase 3 STAR-221 trial comparing domvanalimab plus zimberelimab and FOLFOX with nivolumab plus chemotherapy for first-line advanced gastric, GEJ, or esophageal adenocarcinoma. They discuss why nivolumab plus chemotherapy serves as an appropriate control arm and the importance of head-to-head evidence in clarifying comparative benefit across immunotherapy combinations. They review the study’s primary endpoints and overall goals, including survival outcomes and the potential to redefine the frontline standard.

EP. 4: Where Domvanalimab/Zimberelimab/Chemo Could Fit in the Advanced Gastric/GEJ/Esophageal Adenocarcinoma Paradigm

November 24th 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss the potential clinical implications of the investigation of domvanalimab plus zimberelimab and FOLFOX in gastric/GEJ/esophageal adenocarcinoma.

EP. 5: Ongoing Research to Watch in Advanced Gastric/GEJ Cancer

December 1st 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

EP. 6: Other Key Data in Gastric/GEJ Cancer Presented at ESMO 2025

December 1st 2025

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss other key gastric cancer data presented at the 2025 ESMO Congress.